Literature DB >> 25938290

The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency.

Eeva Piitulainen1, Hanan A Tanash.   

Abstract

The Swedish national register of severe alpha1-antitrypsin (AAT) deficiency was established in 1991. The main aims are to prospectively study the natural history of severe AAT deficiency, and to improve the knowledge of AAT deficiency. The inclusion criteria in the register are age ≥ 18 years, and the PiZ phenotype diagnosed by isoelectric focusing. The register is kept updated by means of repeated questionnaires providing data to allow analysis of the mode of identification, lung and liver function, smoking-habits, respiratory symptoms and diagnoses as reported by physicians. Until February 2014, a total of 1553 PiZZ individuals had been included in the register. The 1102 subjects still alive constituted about 20% of the adult PiZZ individuals in Sweden. Forty-three percent of the subjects had been identified during investigation of respiratory symptoms, 7% by an investigation of liver disease, 26% in an investigation of other pathological conditions, and 24% in a population or family screening. Forty five percent of the subjects had never smoked, 47% were ex-smokers, and 8% current smokers. Twenty-eight percent of the never-smokers, 72% of the ex-smokers, and 61% of the current smokers fulfilled the criteria for COPD with a FEV1/FVC ratio of <0.70. Among the 451 deceased, the most common cause of death was respiratory diseases (55%), followed by liver diseases (13%). We conclude that the detection rate of severe AAT deficiency is relatively high in Sweden. Large numbers of subjects are identified for other reasons than respiratory symptoms, and the majority of these have never smoked.

Entities:  

Keywords:  alpha 1-antitrypsin deficiency; lung function; national register; smoking

Mesh:

Year:  2015        PMID: 25938290     DOI: 10.3109/15412555.2015.1021909

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  11 in total

1.  Hepatic decompensation is accelerated in patients with cirrhosis and alpha-1 antitrypsin Pi∗MZ genotype.

Authors:  Vincent L Chen; Daniel A Burkholder; Isabel J Moran; Jacob V DiBattista; Matthew J Miller; Yanhua Chen; Xiaomeng Du; Antonino Oliveri; Kelly C Cushing; Anna S Lok; Elizabeth K Speliotes
Journal:  JHEP Rep       Date:  2022-04-05

2.  Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden.

Authors:  Hanan A Tanash; Magnus Ekström; Philippe Wagner; Eeva Piitulainen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-07-26

3.  Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population.

Authors:  Hanan Tanash; Magnus Ekström; Nawfal Basil; Eva Rönmark; Anne Lindberg; Eeva Piitulainen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-06-04

4.  Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency.

Authors:  Adriana-Maria Hiller; Eeva Piitulainen; Lars Jehpsson; Hanan Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-23

5.  The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening.

Authors:  Adriana-Maria Hiller; Eeva Piitulainen; Hanan Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-01-05

Review 6.  Alpha-1 antitrypsin deficiency: outstanding questions and future directions.

Authors:  María Torres-Durán; José Luis Lopez-Campos; Miriam Barrecheguren; Marc Miravitlles; Beatriz Martinez-Delgado; Silvia Castillo; Amparo Escribano; Adolfo Baloira; María Mercedes Navarro-Garcia; Daniel Pellicer; Lucía Bañuls; María Magallón; Francisco Casas; Francisco Dasí
Journal:  Orphanet J Rare Dis       Date:  2018-07-11       Impact factor: 4.123

7.  Liver disease in adults with severe alpha-1-antitrypsin deficiency.

Authors:  Hanan A Tanash; Eeva Piitulainen
Journal:  J Gastroenterol       Date:  2019-01-24       Impact factor: 7.527

8.  Heterozygous Genotype rs17580 AT (PiS) in SERPINA1 is Associated with COPD Secondary to Biomass-Burning and Tobacco Smoking: A Case-Control and Populational Study.

Authors:  Gloria Pérez-Rubio; Enrique Ambrocio-Ortiz; Luis A López-Flores; Ana I Juárez-Martín; Luis Octavio Jiménez-Valverde; Susana Zoreque-Cabrera; Gustavo Galicia-Negrete; María Elena Ramírez-Díaz; Filiberto Cruz-Vicente; Manuel de Jesús Castillejos-López; Citlaltepetl Salinas-Lara; Rafael de Jesús Hernández-Zenteno; Alejandra Ramírez-Venegas; Ramcés Falfán-Valencia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-05-27

9.  Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency.

Authors:  Timm Greulich; Alan Altraja; Miriam Barrecheguren; Robert Bals; Jan Chlumsky; Joanna Chorostowska-Wynimko; Christian Clarenbach; Luciano Corda; Angelo Guido Corsico; Ilaria Ferrarotti; Cristina Esquinas; Caroline Gouder; Ana Hećimović; Aleksandra Ilic; Yavor Ivanov; Sabina Janciauskiene; Wim Janssens; Malcolm Kohler; Alvils Krams; Beatriz Lara; Ravi Mahadeva; Gerry McElvaney; Jean-François Mornex; Karen O'Hara; David Parr; Eava Piitulainen; Karin Schmid-Scherzer; Niels Seersholm; Robert A Stockley; Jan Stolk; Maria Sucena; Hanan Tanash; Alice Turner; Ruxandra Ulmeanu; Marion Wilkens; Arzu Yorgancioğlu; Ana Zaharie; Marc Miravitlles
Journal:  ERJ Open Res       Date:  2020-03-02

10.  Lung transplantation and survival outcomes in patients with oxygen-dependent COPD with regard to their alpha-1 antitrypsin deficiency status.

Authors:  Magnus Ekström; Hanan Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.